- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- ROUNDTABLE: Pharmacy’s future in sync with technology
PHILADELPHIA — The Food and Drug Administration has approved a generic version of a short-term adjunct treatment for obesity.
Lannett said that the FDA approved its abbreviated new drug application for phentermine resin extended-release capsules in the 15-mg and 30-mg strengths. The drug, which is equivalent to UCB's Ionamin, will be sold in bariatric clinics.
Lannett’s wholly owned pain management subsidiary, Cody Labs, will produce the active pharmaceutical ingredient for this product. The drug is indicated in the management of exogenous obesity, a form of obesity caused by excessive food intake.